IP Library Granted Patent US 12,440,385
Granted Patent B2
US 12,440,385 · App. 17/547,975 · Granted Oct 14, 2025

Ophthalmic shield and therapeutic apparatus

Inventors: John Gelles (Teaneck, NJ); Jerome Legerton (Jupiter, FL)
Assignee: Ocular Surface Innovations Inc.
A61F9/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,385
App. No.
17/547,975
Granted
Oct 14, 2025
Kind
B2
Abstract

An ophthalmic shield to be worn on an eye is disclosed. In some embodiments, the ophthalmic shield may have a minimum horizontal dimension of 18 mm and a minimum vertical dimension of 15 mm. In some embodiments, the ophthalmic shield may have a minimum horizontal dimension of 20 mm and a minimum vertical dimension of 17 mm. In some embodiments, the ophthalmic shield may have a minimum horizontal dimension of 26 mm and a minimum vertical dimension of 22 mm.

Claims (45)

1. An ophthalmic shield to be worn on a human eye, the ophthalmic shield comprising:

an asymmetrical shape defined by a continuous curvilinear boundary, wherein the boundary is non-annular and lacks a central opening;

a minimum horizontal dimension of 18 mm and a minimum vertical dimension of 15 mm, wherein the ophthalmic shield is configured to extend over and cover both the cornea and at least a portion of the surrounding ocular surface; and

a primary substrate comprising a uniform thickness, being devoid of voids or perforations within its boundary, and comprising an oxygen permeability of greater than 100×10 −11 (cm 2 /sec) (mL O 2 )/(mL×mm Hg).

2. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield is made of a soft material.

3. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield is made of a hydrogel or silicone hydrogel material.

4. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield is a soft material having less than 2% water content.

5. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield is made of polydimethylsiloxane (PDMS).

6. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield comprises a smooth, continuous, and symmetric boundary forming a substantially circular or elliptical shape.

7. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield comprises a non-uniform, asymmetric, or irregular boundary.

8. The ophthalmic shield of claim 1 , wherein the ophthalmic shield conforms to the contour of the sclera of the human eye.

9. The ophthalmic shield of claim 1 , wherein the ophthalmic shield contains an optic zone for optical correction for the human eye.

10. The ophthalmic shield of claim 1 wherein the ophthalmic shield does not contain an optic zone for optical correction for the human eye.

11. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield comprises a single modulus of elasticity.

12. The ophthalmic shield of claim 1 , wherein the primary substrate of the ophthalmic shield comprises ultra-high water vapor permeability.

13. An ophthalmic shield to be worn on a human eye, the ophthalmic shield comprising:

an asymmetrical shape defined by a curvilinear boundary, wherein the boundary is non-annular and lacks a central opening;

a minimum horizontal dimension of 20 mm and a minimum vertical dimension of 17 mm, wherein the ophthalmic shield is configured to extend over and cover both the cornea and at least a portion of the surrounding ocular surface; and

a primary substrate comprising a uniform thickness, being devoid of voids or perforations within its boundary, and comprising an oxygen permeability of greater than 100×10 −11 (cm 2 /sec) (mL O 2 )/(mL×mm Hg).

14. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield is made of a soft material.

15. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield is made of a hydrogel or silicone hydrogel material.

16. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield is a soft material having less than 2% water content.

17. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield is made of polydimethylsiloxane (PDMS).

18. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield comprises a smooth, continuous, and symmetric boundary forming a substantially circular or elliptical shape.

19. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield comprises a non-uniform, asymmetric, or irregular boundary.

20. The ophthalmic shield of claim 13 , wherein the ophthalmic shield conforms to the contour of the sclera of the human eye.

21. The ophthalmic shield of claim 13 , wherein the ophthalmic shield contains an optic zone for optical correction for the human eye.

22. The ophthalmic shield of claim 13 wherein the ophthalmic shield does not contain an optic zone for optical correction for the human eye.

23. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield comprises a single modulus of elasticity.

24. The ophthalmic shield of claim 13 , wherein the primary substrate of the ophthalmic shield comprises ultra-high water vapor permeability.

25. An ophthalmic shield to be worn on a human eye, the ophthalmic shield comprising:

an asymmetrical shape defined by a curvilinear boundary, wherein the boundary is non-annular and lacks a central opening;

a minimum horizontal dimension of 26 mm and a minimum vertical dimension of 22 mm, wherein the ophthalmic shield is configured to extend over and cover both the cornea and at least a portion of the surrounding ocular surface; and

a primary substrate comprising a uniform thickness, being devoid of voids or perforations within its boundary, and comprising an oxygen permeability of greater than 100×10 −11 (cm 2 /sec) (mL O 2 )/(mL×mm Hg).

26. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield is made of a soft material.

27. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield is made of a hydrogel or silicone hydrogel material.

28. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield is a soft material having less than 2% water content.

29. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield is made of polydimethylsiloxane (PDMS).

30. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield comprises a smooth, continuous, and symmetric boundary forming a substantially circular or elliptical shape.

31. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield comprises a non-uniform, asymmetric, or irregular boundary.

32. The ophthalmic shield of claim 25 , wherein the ophthalmic shield conforms to the contour of the sclera of the human eye.

33. The ophthalmic shield of claim 25 , wherein the ophthalmic shield contains an optic zone for optical correction for the human eye.

34. The ophthalmic shield of claim 25 wherein the ophthalmic shield does not contain an optic zone for optical correction for the human eye.

35. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield comprises a single modulus of elasticity.

36. The ophthalmic shield of claim 25 , wherein the primary substrate of the ophthalmic shield comprises ultra-high water vapor permeability.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2025
From: GELLES, JOHN; LEGERTON, JEROME
To: OCULAR SURFACE INNOVATIONS INC.
Reel/Frame 072223/0533 →
Continuity (1)
Related Publication 20230181370A1 · Jun 15, 2023
References Cited (40)
US 4084890A · Baron · 1978 [cited by applicant]
US 5100225A · Rothe · 1992 [cited by applicant]
US 6093868A · Sawano et al. · 2000 [cited by applicant]
US 8459793B2 · De Juan, Jr. et al. · 2013 [cited by applicant]
US 8591025B1 · De Juan, Jr. et al. · 2013 [cited by applicant]
US 8678584B2 · De Juan, Jr. et al. · 2014 [cited by applicant]
US 8864306B2 · De Juan, Jr. et al. · 2014 [cited by applicant]
US 8926096B2 · De Juan, Jr. et al. · 2015 [cited by applicant]
US 9107773B2 · De Juan, Jr. et al. · 2015 [cited by applicant]
US 9241837B2 · De Juan, Jr. et al. · 2016 [cited by applicant]
US 9341864B2 · De Juan, Jr. et al. · 2016 [cited by applicant]
US 9395558B2 · De Juan, Jr. et al. · 2016 [cited by applicant]
US 9423632B2 · De Juan, Jr. et al. · 2016 [cited by applicant]
US 9465233B2 · De Juan, Jr. et al. · 2016 [cited by applicant]
US 9498385B2 · De Juan, Jr. et al. · 2016 [cited by applicant]
US 9740025B2 · De Juan, Jr. et al. · 2017 [cited by applicant]
US 9740026B2 · De Juan, Jr. et al. · 2017 [cited by applicant]
US 9810921B2 · De Juan, Jr. et al. · 2017 [cited by applicant]
US 9851856B2 · De Juan, Jr. et al. · 2017 [cited by applicant]
US 10036900B2 · De Juan, Jr. et al. · 2018 [cited by applicant]
US 10039671B2 · De Juan, Jr. et al. · 2018 [cited by applicant]
US 10191303B2 · De Juan, Jr. et al. · 2019 [cited by applicant]
US 20040181240A1 · Tseng et al. · 2004 [cited by applicant]
US 20080148461A1 · Guyuron et al. · 2008 [cited by applicant]
US 20080243095A1 · Kaiser · 2008 [cited by examiner]
US 20120310133A1 · De Juan, Jr. · 2012 [cited by examiner]
US 20140155800A1 · de Juan, Jr. · 2014 [cited by examiner]
US 20170329052A1 · Chan · 2017 [cited by applicant]
US 20180129073A1 · Meyers · 2018 [cited by examiner]
US 20190101669A1 · Yee et al. · 2019 [cited by applicant]
US 20200004047A1 · de Juan et al. · 2020 [cited by applicant]
US 20200038240A1 · de Juan, Jr. · 2020 [cited by examiner]
WO 2014148922A2 · 2014 [cited by applicant]
Hirabayashi, Kristin E et al. “Prospective, Randomized, Eye-to-Eye Comparison of a New Silicone Corneal Shield versus Conventional Bandage Contact Lens after Photorefractive Keratectomy.” Journal of cataract and refract… [cited by examiner]
Jacobs, Deborah S et al. “Clear—Medical Use of Contact Lenses.” Contact lens & anterior eye 44.2 (2021): 289-329. Web. (Year: 2021). [cited by examiner]
Ehrmann, https://web.archive.org/web/20181212062103/http:/www.siliconehydrogels.org/editorials/may_05.asp (Year: 2018). [cited by examiner]
Hirabayashi, Kristin E. et al., “Prospective, randomized, eye-to-eye comparison of a new silicone corneal shield versus conventional bandage contact lens after photorefractive keratoectomy,” J Cataract Refract Surg 2019… [cited by applicant]
Jacobs, Deborah S. et al., “Clear—Medical Use of Contact Lenses,” Contact Lens and Anterior Eye, 2021; pp. 289-329; vol. 44. [cited by applicant]
PCT International Search Report and the Written Opinion mailed Mar. 3, 2023, issued in related International Application No. PCT/US2022/050624 (10 pages). [cited by applicant]
PCT International Search Report and the Written Opinion mailed Mar. 6, 2023, issued in related International Application No. PCT/US2022/050629 (11 pages). [cited by applicant]